

Extension of Offers under Prospectus

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), refers to the offers ("Offers") under the prospectus lodged to ASIC and ASX on 22 December 2022 ("Prospectus").

The Company advises that it has extended the Offers under the Prospectus for a period of one week. The revised timetable is set out below and shows a new Closing Date of 20 January 2023.

| Indicative Timetable | Date |
|---|------------------------------------|
| Announcement of the Placement and Appendix 3B | 28 October 2022 |
| Lodgement of Prospectus with ASIC and the ASX | 22 December 2022 |
| Opening Date of the Offers | 22 December 2022 |
| Closing Date of the Offers | 5:00pm (WST) on 20 January 2023 |
| Issue of Securities | 25 January 2023 |
| Despatch of Holding Statements for Securities and application made to ASX for quotation of the Securities | 25 January 2023 |

The Company reserves the right to further vary the above timetable in its discretion, without warning, subject to ASX Listing Rules.

Only Eligible Shareholders may subscribe for the Offers. Eligible Shareholders in the Placement Option Offer are the participants in the placement announced on 28 October 2022 ("Placement Participants").

Placement Participants may accept their offer online by following the steps below:

1. Go to <https://investor.automic.com.au/#/home>
2. Login with your existing Username and Password - if you have not yet established an online account, visit <https://investor.automic.com.au/#/signup>
3. Once you are logged in, select "Offers" from the left-hand vertical menu and follow the prompts.
4. Select "Neurotech International Limited" from the dropdown list in the Issuer Name Field
5. Enter your Holder Reference (SRN/HIN)
6. Enter your postcode OR country of residence (only if outside Australia)
7. Tick the box "I'm not a robot" and then select "Next"
8. Complete the prompts to set up your username and password details
9. Once you are logged in, select "Offers" from the left-hand vertical menu and follow the prompts.

Authority

This announcement has been authorised for release by the Executive Director of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.